On therapeutics, the WHO chief said that the first proven therapy for severe COVID-19, Dexamethasone, was announced in June with support from the plan's therapeutic accelerator arm and is currently in scale-up.
"On diagnostics, more than 50 tests are currently in evaluation, and new evidence has been generated around rapid antigen detection tests that could be game-changing," he noted.
However, the WHO chief told reporters that the ACT-Accelerator plan is now facing a huge financial shortage and "it must be financed to be successful."
Earlier this week, Tedros said that the plan has only received 10 percent of what is needed.
"It's easy to think of the ACT-Accelerator as a research and development effort, but in reality it's the best economic stimulus the world can invest," he said.
Mentioning that within the first two weeks of January, the viral genome of COVID-19 was mapped in China and shared globally, Tedros stressed that as the pandemic evolved, countries needed to come together in an unprecedented way.
"Today, I want to talk about not how we're going to go back but how we're going to go forward. And that to move forward, the best bet is to do it together," Tedros said.
He pointed out that excess demand and competition for supply are already creating "vaccine nationalism" and the risk of price gouging.
"This is the kind of market failure that only global solidarity, public sector investment and engagement can solve," he stressed.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.